DFTX
Definium TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
+
Peers tracked
10
U.S. public peers
Grade Position
Below peers
vs peer average
DFTX vs peer average
23/100
DFTX vs. peer average (F vs. C)
Grade spread
A 2 · B 1 · C 1 · D 4 · F 2
Graded peers loaded
Coverage
10 graded
100% of tracked
Peer overview
RAPP is the first available peer comparator.
Rapport Therapeutics is a more relevant operating peer than broad-cap biotech because both are CNS-focused clinical-stage companies valued primarily on pipeline execution rather than current product revenue. The comparison underscores how sharply DFTX can rerate on credible clinical milestones, but it also highlights that evidence quality can change quickly after any disappointing readout.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
DFTX
Definium Therapeutics
RAPP
Rapport Therapeutics
Grade
F
D
Momentum
57
78
Value
41
41
Sentiment
12
46
Setup Bias
Net —
-
Market Cap
-
-
Posture
Defensive
Defensive
Grade position vs RAPP
DFTX / RAPP
Grade Position
Below peers
DFTX vs. peer average (F vs. C)
23/100
Momentum
57
RAPPValue
41
DFTXSentiment
12
RAPPRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs DFTX
RAPP is the first peer returned for this comparison set.